Last reviewed · How we verify

BNT162a1

BioNTech SE · Phase 1 active Biologic

BNT162a1 is a mRNA-based vaccine candidate developed by BioNTech SE for COVID-19. It has completed Phase 1 and Phase 2 trials, demonstrating safety and immunogenicity in healthy and immunocompromised adults. The vaccine is part of a broader portfolio of BNT162 candidates, but it has not received regulatory approval.

At a glance

Generic nameBNT162a1
SponsorBioNTech SE
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.